Subsequently, the PD-1 inhibitor pembrolizumab and the PD-L1 inhibitor Atezolizumab showed comparable efficacy, leading to a paradigm shift in the treatment of advanced NSCLC [3,4]. Here, CD274 is linked to non-small cell lung carcinoma.